[1] |
KATZEN J, BEERS M F. Contributions of alveolar epithelial cell quality control to pulmonary fibrosis[J]. J Clin Invest, 2020, 130(10):5088-5099. doi:10.1172/JCI139519.
|
[2] |
MA H B, WU X Y, LI Y, et al. Research progress in the molecular mechanisms,therapeutic targets,and drug development of idiopathic pulmonary fibrosis[J]. Front Pharmacol, 2022, 13:963054. doi:10.3389/fphar.2022.963054.
|
[3] |
COX I A, OTAHAL P, DE GRAAFF B, et al. Incidence,prevalence and mortality of idiopathic pulmonary fibrosis in Australia[J]. Respirology, 2022, 27(3):209-216. doi:10.1111/resp.14194.
|
[4] |
VANCHERI C, KREUTER M, RICHELDI L, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis. results of the INJOURNEY trial[J]. Am J Respir Crit Care Med, 2018, 197(3):356-363. doi:10.1164/rccm.201706-1301OC.
|
[5] |
BRIDGES M C, DAULAGALA A C, KOURTIDIS A. LNCcation:lncRNA localization and function[J]. J Cell Biol, 2021, 220(2):e202009045. doi:10.1083/jcb.202009045.
|
[6] |
ZHANG T, YU S, ZHAO S. LncRNA FEZF1-AS1 promotes colorectal cancer progression through regulating the miR-363-3p/PRRX1 pathway[J]. Adv Clin Exp Med, 2021, 30(8):839-848. doi:10.17219/acem/135693.
|
[7] |
PONTEMEZZO E, FOGLIO E, VERNUCCI E, et al. miR-200c-3p regulates epitelial-to-mesenchymal transition in epicardial mesothelial cells by targeting epicardial follistatin-related protein 1[J]. Int J Mol Sci, 2021, 22(9):4971. doi:10.3390/ijms22094971.
|
[8] |
WANG Y, LU K, LI W, et al. MiR-200c-3p aggravates gastric cell carcinoma via KLF6[J]. Genes Genomics, 2021, 43(11):1307-1316. doi:10.1007/s13258-021-01160-6.
|
[9] |
KURUNDKAR A R, KURUNDKAR D, RANGARAJAN S, et al. The matricellular protein CCN1 enhances TGF-β1/SMAD3-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to lung injury[J]. FASEB J, 2016, 30(6):2135-2150. doi:10.1096/fj.201500173.
|
[10] |
HERMAN A B, TSITSIPATIS D, GOROSPE M. Integrated lncRNA function upon genomic and epigenomic regulation[J]. Mol Cell, 2022, 82(12):2252-2266. doi:10.1016/j.molcel.2022.05.027.
|
[11] |
WANG H, WU Y, WANG Z, et al. The LncRNA FEZF1-AS1 promotes tumor proliferation in colon cancer by regulating the mitochondrial protein PCK2[J]. Oncol Res, 2022, 29(3):201-215. doi:10.32604/or.2022.03553.
|
[12] |
LIANG M, LI Y, DAI T, et al. lncRNA FEZF1-AS1 regulates biological behaviors of cervical cancer by targeting miRNA-1254[J]. Food Sci Nutr, 2021, 9(9):4722-4737. doi:10.1002/fsn3.2315.
|
[13] |
HE R, ZHANG F H, SHEN N. LncRNA FEZF1-AS1 enhances epithelial-mesenchymal transition (EMT) through suppressing E-cadherin and regulating WNT pathway in non-small cell lung cancer (NSCLC)[J]. Biomed Pharmacother, 2017, 95:331-338. doi:10.1016/j.biopha.2017.08.057.
|
[14] |
WANG Z H, WANG J H, WANG K Q, et al. LncRNA FEZF1-AS1 promoted chemoresistance,autophagy and epithelial-mesenchymal transition (EMT) through regulation of miR-25-3p/ITGB8 axis in prostate cancer[J]. Eur Rev Med Pharmacol Sci, 2020, 24(16):8250. doi:10.26355/eurrev_202008_22591.
|
[15] |
WANG Y D, SUN X J, YIN J J, et al. Long non-coding RNA FEZF1-AS1 promotes cell invasion and epithelial-mesenchymal transition through JAK2/STAT3 signaling pathway in human hepatocellular carcinoma[J]. Biomed Pharmacother, 2018, 106:134-141. doi:10.1016/j.biopha.2018.05.116.
|
[16] |
MOIMAS S, SALTON F, KOSMIDER B, et al. miR-200 family members reduce senescence and restore idiopathic pulmonary fibrosis type II alveolar epithelial cell transdifferentiation[J]. ERJ Open Res, 2019, 5(4):00138-2019. doi:10.1183/23120541.00138-2019.
|
[17] |
LIN S, ZHANG R, XU L, et al. LncRNA Hoxaas3 promotes lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1[J]. Cell Death Dis, 2020, 11(8):706. doi:10.1038/s41419-020-02889-w.
|